MET097

DRUG4 trials

Sponsors

Pfizer

Conditions

ObesityObesity and Obesity-related Medical ConditionsObesity and OverweightOverweight or Obesity

Phase 1

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

RecruitingNCT06924320

PfizerObesity and Obesity-related Medical Conditions

Start: 2025-03-06End: 2026-09-15Target: 381Updated: 2026-06-01

Phase 2

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

CompletedNCT06712836

PfizerObesity, Overweight or Obesity

Start: 2024-10-09End: 2026-04-30Updated: 2026-08-28

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Active, not recruitingNCT06973720

PfizerObesity, Overweight or Obesity

Start: 2025-04-07End: 2026-10-16Updated: 2026-05-29

Phase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Active, not recruitingNCT07311850

PfizerObesity and Overweight

Start: 2025-12-19End: 2028-04-25Updated: 2026-09-04